A specific anti-cyclin D1 intrabody represses breast cancer cell proliferation by interrupting the cyclin D1-CDK4 interaction
- PMID: 36808524
- DOI: 10.1007/s10549-023-06866-7
A specific anti-cyclin D1 intrabody represses breast cancer cell proliferation by interrupting the cyclin D1-CDK4 interaction
Abstract
Background: Cyclin D1 overexpression may contribute to development of various cancers, including breast cancer, and thus may serve as a key cancer diagnostic marker and therapeutic target. In our previous study, we generated a cyclin D1-specific single-chain variable fragment antibody (ADκ) from a human semi-synthetic single-chain variable fragment library. ADκ specifically interacted with recombinant and endogenous cyclin D1 proteins through an unknown molecular basis to inhibit HepG2 cell growth and proliferation.
Results: Here, using phage display and in silico protein structure modeling methods combined with cyclin D1 mutational analysis, key residues that bind to ADκ were identified. Notably, residue K112 within the cyclin box was required for cyclin D1-ADκ binding. In order to elucidate the molecular mechanism underlying ADκ anti-tumor effects, a cyclin D1-specific nuclear localization signal-containing intrabody (NLS-ADκ) was constructed. When expressed within cells, NLS-ADκ interacted specifically with cyclin D1 to significantly inhibit cell proliferation, induce G1-phase arrest, and trigger apoptosis of MCF-7 and MDA-MB-231 breast cancer cells. Moreover, the NLS-ADκ-cyclin D1 interaction blocked binding of cyclin D1 to CDK4 and inhibited RB protein phosphorylation, resulting in altered expression of downstream cell proliferation-related target genes.
Conclusion: We identified amino acid residues in cyclin D1 that may play key roles in the ADκ-cyclin D1 interaction. A nuclear localization antibody against cyclin D1 (NLS-ADκ) was constructed and successfully expressed in breast cancer cells. NLS-ADκ exerted tumor suppressor effects via blocking the binding of CDK4 to cyclin D1 and inhibiting phosphorylation of RB. The results presented here demonstrate anti-tumor potential of intrabody-based cyclin D1-targeted breast cancer therapy.
Keywords: Breast cancer; Cell proliferation; Cyclin D1; Epitope; Intrabody; Single-chain variable fragment.
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
A Cyclin D1-Specific Single-Chain Variable Fragment Antibody that Inhibits HepG2 Cell Growth and Proliferation.Biotechnol J. 2020 Aug;15(8):e1900430. doi: 10.1002/biot.201900430. Epub 2020 Mar 29. Biotechnol J. 2020. PMID: 32170989
-
Validation of cyclin D1/CDK4 as an anticancer drug target in MCF-7 breast cancer cells: Effect of regulated overexpression of cyclin D1 and siRNA-mediated inhibition of endogenous cyclin D1 and CDK4 expression.Breast Cancer Res Treat. 2006 Jan;95(2):185-94. doi: 10.1007/s10549-005-9066-y. Epub 2005 Dec 1. Breast Cancer Res Treat. 2006. PMID: 16319987
-
Anticancer activity of britannin through the downregulation of cyclin D1 and CDK4 in human breast cancer cells.J Cancer Res Ther. 2019 Jul-Sep;15(5):1105-1108. doi: 10.4103/jcrt.JCRT_517_17. J Cancer Res Ther. 2019. PMID: 31603118
-
Bisphenol S promotes the cell cycle progression and cell proliferation through ERα-cyclin D-CDK4/6-pRb pathway in MCF-7 breast cancer cells.Toxicol Appl Pharmacol. 2019 Mar 1;366:75-82. doi: 10.1016/j.taap.2019.01.017. Epub 2019 Jan 23. Toxicol Appl Pharmacol. 2019. PMID: 30684532
-
Location, location, location: the role of cyclin D1 nuclear localization in cancer.J Cell Biochem. 2005 Dec 1;96(5):906-13. doi: 10.1002/jcb.20613. J Cell Biochem. 2005. PMID: 16163738 Review.
Cited by
-
TLR2 and TLR9 Blockade Using Specific Intrabodies Inhibits Inflammation-Mediated Pancreatic Cancer Cell Growth.Antibodies (Basel). 2024 Feb 1;13(1):11. doi: 10.3390/antib13010011. Antibodies (Basel). 2024. PMID: 38390872 Free PMC article.
-
Transient intracellular expression of PD-L1 and VEGFR2 bispecific nanobody in cancer cells inspires long-term T cell activation and infiltration to combat tumor and inhibit cancer metastasis.Mol Cancer. 2025 Apr 19;24(1):119. doi: 10.1186/s12943-025-02253-6. Mol Cancer. 2025. PMID: 40253320 Free PMC article.
-
Avellanin A Has an Antiproliferative Effect on TP-Induced RWPE-1 Cells via the PI3K-Akt Signalling Pathway.Mar Drugs. 2024 Jun 13;22(6):275. doi: 10.3390/md22060275. Mar Drugs. 2024. PMID: 38921586 Free PMC article.
References
-
- Matthews HK, Bertoli C, de Bruin RAM (2022) Cell cycle control in cancer. Nat Rev Mol Cell Biol 23(1):74–88. https://doi.org/10.1038/s41580-021-00404-3 - DOI - PubMed
-
- Goel S, Bergholz J, Zhao J (2022) Targeting CDK4 and CDK6 in cancer. Nat Rev Cancer. https://doi.org/10.1038/s41568-022-00456-3 - DOI - PubMed - PMC
-
- Fassl A, Geng Y, Sicinski P (2022) CDK4 and CDK6 kinases: from basic science to cancer therapy. Science 375(6577):eabc1495. https://doi.org/10.1126/science.abc1495 - DOI - PubMed - PMC
-
- Hume S, Dianov G, Ramadan K (2020) A unified model for the G1/S cell cycle transition. Nucleic Acids Res 48(22):12483–12501. https://doi.org/10.1093/nar/gkaa1002 - DOI - PubMed - PMC
-
- Qie S, Diehl JA (2020) Cyclin D degradation by E3 ligases in cancer progression and treatment. Semin Cancer Biol 67(Pt 2):159–170. https://doi.org/10.1016/j.semcancer.2020.01.012 - DOI - PubMed - PMC
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous